On Feb. 19, 2021, Luminex announced that it had received $11.3 million in funding from the Biomedical Advanced Research and Development Authority (BARDA). These funds support the rapid development and validation of a respiratory panel combining Flu A/B & respiratory syncytial virus (RSV) targets with the SARS-CoV-2 target that can be run on all ARIESﾮ Systems.

These 6- and 12-cassette systems are automated molecular diagnostic platforms used in moderate- and high-complexity labs with a number of FDA cleared tests already available for use on them. The systems produce results in less than two hours with minimal hands-on time required.